Industry Research Reports
Home > Reports > Pharma & Healthcare > Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
NAD+ Intravenous Therapy Market Size(US$)
CAGR 2026-2032
8.3%
Market Size,2032
USD 171
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 106 million
Market Forecast in 2032(Value)
US$ 171 million
CAGR
8.3%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global NAD+ Intravenous Therapy market size was US$ 99 million in 2025 and is forecast to reach a readjusted size of US$ 171 million by 2032 with a CAGR of 8.3% during the forecast period 2026-2032.
NAD+ IV Therapy is a wellness therapy that involves the intravenous administration of nicotinamide adenine dinucleotide (NAD+), a coenzyme crucial for cellular energy production and metabolic processes. This therapy is believed to boost energy levels, enhance cognitive function, and promote overall cellular repair by increasing NAD+ levels, which naturally decline with age.
1. Evidence-Driven Transition: NAD⁺ IV Therapy Is Shifting from Concept-Based Anti-Aging to Clinically Validated Intervention
The most fundamental long-term trend for NAD⁺ anti-aging intravenous therapy is its transition from a concept-driven wellness service toward an evidence-based clinical intervention. At present, most claimed benefits of NAD⁺ IV—such as anti-fatigue, cognitive enhancement, metabolic optimization, and longevity—are primarily supported by mechanistic studies, animal models, or small observational trials, rather than large-scale randomized controlled trials (RCTs). As regulatory scrutiny increases and medical institutions demand higher scientific rigor, the industry will be forced to generate robust clinical evidence to validate therapeutic outcomes, define clear clinical indications, and demonstrate measurable improvements in objective biomarkers. Over time, NAD⁺ IV is expected to evolve from a loosely defined “anti-aging treatment” into a medically framed intervention with specific use cases, patient stratification, and standardized clinical endpoints.
2. Regulatory Tightening: NAD⁺ IV Therapy Is Moving from a Gray Market into a Strongly Regulated Medical Framework
Another highly certain trend is the progressive tightening of regulatory oversight, which will push NAD⁺ intravenous therapy out of its current semi-gray commercial zone and into a strictly regulated medical framework. In many markets today, NAD⁺ IV is delivered through medical spas, wellness clinics, or functional medicine centers, often without clearly approved indications, standardized drug registration status, or consistent compliance with pharmaceutical regulations. As governments strengthen control over injectable therapies, compounded drugs, and medical advertising, NAD⁺ IV services will increasingly be required to meet formal regulatory standards related to drug sourcing, sterile preparation, clinical justification, physician supervision, and liability management. This regulatory shift will significantly raise entry barriers and is expected to eliminate a large number of low-compliance providers, while favoring hospital systems, licensed clinics, and medically integrated institutions.
3. Safety and Quality Dominance: Sterility, Endotoxin Control, and Supply Chain Integrity Will Become Core Competitive Factors
Safety and pharmaceutical-grade quality control will become the central competitive axis of the NAD⁺ IV industry as it matures. Intravenous administration inherently carries higher systemic risks than oral supplementation, placing stringent demands on sterile manufacturing, endotoxin control, formulation stability, dosage consistency, and cold-chain logistics. Currently, the market exhibits significant heterogeneity in raw material sourcing, preparation standards, and clinical protocols, creating potential safety vulnerabilities. In the future, sustainable operators will be those capable of implementing GMP-level production systems, batch traceability, sterility validation, adverse-event monitoring, and standardized infusion procedures. As a result, NAD⁺ IV therapy will gradually resemble a pharmaceutical medical service rather than a consumer wellness product, with safety compliance itself becoming a major structural barrier to entry.
4. Product Pathway Differentiation: IV Administration Will Become a High-End Niche While Scalable Alternatives Expand
From a product strategy perspective, NAD⁺ IV therapy is structurally constrained from becoming a mass-market solution due to its high operational costs, time-intensive administration, medical dependency, and variability in patient tolerance. As research and commercialization of NAD⁺ precursors and alternative delivery methods continue to advance, market demand will increasingly shift toward more scalable, standardized, and consumer-friendly pathways. In this context, intravenous NAD⁺ will gradually reposition itself as a premium, specialized intervention within functional medicine, longevity clinics, and rehabilitation medicine, while larger market volumes will be captured by non-IV solutions. Long term, NAD⁺ IV is more likely to remain a precision medical tool for specific high-value scenarios rather than a mainstream anti-aging modality.
5. Business Model Evolution: From One-Time Anti-Aging Services to Longitudinal Medical Management Systems
The commercial model of NAD⁺ IV therapy is expected to evolve from transaction-based “anti-aging packages” toward longitudinal medical management systems centered on patient stratification and data feedback. As consumers become more scientifically informed and regulators restrict exaggerated longevity claims, simple service-selling models will lose sustainability. Instead, leading providers will integrate NAD⁺ IV into broader functional medicine frameworks, supported by baseline diagnostics, biomarker tracking, patient segmentation, and outcome monitoring. In this emerging model, NAD⁺ IV is no longer positioned as a standalone product, but as one component within a personalized health optimization ecosystem, where long-term value is generated through continuous medical engagement, data accumulation, and outcome-based service delivery.
The global NAD+ Intravenous Therapy market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company
- The Wellness Lab
- Conciergemdla
- Azivmedics
- Reset IV
- Thedripclub
- Toronto Functional Medicine Centre
- Mobileivmedics
- Rocky Mountain Ivmedics
- Premiumhealth
- Effect Doctors
- Nadclinic
- Hydrate IV Bar
- LIVV Natural
- BioReset Medical
- IV Boost UK
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- NAD+ Mixed Vitamin Injections
- Pure NAD+ Injection
Segment by Application
- Clinic
- Hospital
- Others
Segment by Category
- Single-use Injection Type
- Recurring Injection Type
- Others
Segment by Division
- Low-dose Type
- Medium-dose Type
- High-dose Type
QYResearch's Strengths
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 NAD+ Mixed Vitamin Injections
1.2.3 Pure NAD+ Injection
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global NAD+ Intravenous Therapy Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global NAD+ Intravenous Therapy Market Share by Revenue, by Region (2021-2026)
2.4 Global NAD+ Intravenous Therapy Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America NAD+ Intravenous Therapy Market Size and Prospective (2021-2032)
2.5.2 Europe NAD+ Intravenous Therapy Market Size and Prospective (2021-2032)
2.5.3 Asia-Pacific NAD+ Intravenous Therapy Market Size and Prospective (2021-2032)
2.5.4 Latin America NAD+ Intravenous Therapy Market Size and Prospective (2021-2032)
2.5.5 Middle East & Africa NAD+ Intravenous Therapy Market Size and Prospective (2021-2032)
3 Breakdown Data by Type
3.1 Global NAD+ Intravenous Therapy Historical Market Size by Type (2021-2026)
3.2 Global NAD+ Intravenous Therapy Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of NAD+ Intravenous Therapy
4 Breakdown Data by Application
4.1 Global NAD+ Intravenous Therapy Historical Market Size by Application (2021-2026)
4.2 Global NAD+ Intravenous Therapy Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in NAD+ Intravenous Therapy Applications
5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top NAD+ Intravenous Therapy Players by Revenue (2021-2026)
5.1.2 Global NAD+ Intravenous Therapy Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by NAD+ Intravenous Therapy Revenue
5.4 Global NAD+ Intravenous Therapy Market Concentration Analysis
5.4.1 Global NAD+ Intravenous Therapy Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by NAD+ Intravenous Therapy Revenue in 2025
5.5 Global Key Players of NAD+ Intravenous Therapy Head Offices and Areas Served
5.6 Global Key Players of NAD+ Intravenous Therapy, Product and Application
5.7 Global Key Players of NAD+ Intravenous Therapy, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America NAD+ Intravenous Therapy Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America NAD+ Intravenous Therapy Market Size by Type (2021-2026)
6.1.2.2 North America NAD+ Intravenous Therapy Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America NAD+ Intravenous Therapy Market Size by Application (2021-2026)
6.1.3.2 North America NAD+ Intravenous Therapy Market Share by Application (2021-2026)
6.1.4 North America NAD+ Intravenous Therapy Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe NAD+ Intravenous Therapy Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe NAD+ Intravenous Therapy Market Size by Type (2021-2026)
6.2.2.2 Europe NAD+ Intravenous Therapy Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe NAD+ Intravenous Therapy Market Size by Application (2021-2026)
6.2.3.2 Europe NAD+ Intravenous Therapy Market Share by Application (2021-2026)
6.2.4 Europe NAD+ Intravenous Therapy Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers
6.3.1 Asia-Pacific NAD+ Intravenous Therapy Revenue by Company (2021-2026)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific NAD+ Intravenous Therapy Market Size by Type (2021-2026)
6.3.2.2 Asia-Pacific NAD+ Intravenous Therapy Market Share by Type (2021-2026)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific NAD+ Intravenous Therapy Market Size by Application (2021-2026)
6.3.3.2 Asia-Pacific NAD+ Intravenous Therapy Market Share by Application (2021-2026)
6.3.4 Asia-Pacific NAD+ Intravenous Therapy Major Customers
6.3.5 Asia-Pacific Market Trends and Opportunities
6.4 Latin America Market: Players, Segments, Downstream and Major Customers
6.4.1 Latin America NAD+ Intravenous Therapy Revenue by Company (2021-2026)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America NAD+ Intravenous Therapy Market Size by Type (2021-2026)
6.4.2.2 Latin America NAD+ Intravenous Therapy Market Share by Type (2021-2026)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America NAD+ Intravenous Therapy Market Size by Application (2021-2026)
6.4.3.2 Latin America NAD+ Intravenous Therapy Market Share by Application (2021-2026)
6.4.4 Latin America NAD+ Intravenous Therapy Major Customers
6.4.5 Latin America Market Trends and Opportunities
6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers
6.5.1 Middle East & Africa NAD+ Intravenous Therapy Revenue by Company (2021-2026)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa NAD+ Intravenous Therapy Market Size by Type (2021-2026)
6.5.2.2 Middle East & Africa NAD+ Intravenous Therapy Market Share by Type (2021-2026)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa NAD+ Intravenous Therapy Market Size by Application (2021-2026)
6.5.3.2 Middle East & Africa NAD+ Intravenous Therapy Market Share by Application (2021-2026)
6.5.4 Middle East & Africa NAD+ Intravenous Therapy Major Customers
6.5.5 Middle East & Africa Market Trends and Opportunities
7 Key Player Profiles
7.1 The Wellness Lab
7.1.1 The Wellness Lab Company Details
7.1.2 The Wellness Lab Business Overview
7.1.3 The Wellness Lab NAD+ Intravenous Therapy Introduction
7.1.4 The Wellness Lab Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.1.5 The Wellness Lab Recent Development
7.2 Conciergemdla
7.2.1 Conciergemdla Company Details
7.2.2 Conciergemdla Business Overview
7.2.3 Conciergemdla NAD+ Intravenous Therapy Introduction
7.2.4 Conciergemdla Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.2.5 Conciergemdla Recent Development
7.3 Azivmedics
7.3.1 Azivmedics Company Details
7.3.2 Azivmedics Business Overview
7.3.3 Azivmedics NAD+ Intravenous Therapy Introduction
7.3.4 Azivmedics Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.3.5 Azivmedics Recent Development
7.4 Reset IV
7.4.1 Reset IV Company Details
7.4.2 Reset IV Business Overview
7.4.3 Reset IV NAD+ Intravenous Therapy Introduction
7.4.4 Reset IV Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.4.5 Reset IV Recent Development
7.5 Thedripclub
7.5.1 Thedripclub Company Details
7.5.2 Thedripclub Business Overview
7.5.3 Thedripclub NAD+ Intravenous Therapy Introduction
7.5.4 Thedripclub Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.5.5 Thedripclub Recent Development
7.6 Toronto Functional Medicine Centre
7.6.1 Toronto Functional Medicine Centre Company Details
7.6.2 Toronto Functional Medicine Centre Business Overview
7.6.3 Toronto Functional Medicine Centre NAD+ Intravenous Therapy Introduction
7.6.4 Toronto Functional Medicine Centre Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.6.5 Toronto Functional Medicine Centre Recent Development
7.7 Mobileivmedics
7.7.1 Mobileivmedics Company Details
7.7.2 Mobileivmedics Business Overview
7.7.3 Mobileivmedics NAD+ Intravenous Therapy Introduction
7.7.4 Mobileivmedics Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.7.5 Mobileivmedics Recent Development
7.8 Rocky Mountain Ivmedics
7.8.1 Rocky Mountain Ivmedics Company Details
7.8.2 Rocky Mountain Ivmedics Business Overview
7.8.3 Rocky Mountain Ivmedics NAD+ Intravenous Therapy Introduction
7.8.4 Rocky Mountain Ivmedics Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.8.5 Rocky Mountain Ivmedics Recent Development
7.9 Premiumhealth
7.9.1 Premiumhealth Company Details
7.9.2 Premiumhealth Business Overview
7.9.3 Premiumhealth NAD+ Intravenous Therapy Introduction
7.9.4 Premiumhealth Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.9.5 Premiumhealth Recent Development
7.10 Effect Doctors
7.10.1 Effect Doctors Company Details
7.10.2 Effect Doctors Business Overview
7.10.3 Effect Doctors NAD+ Intravenous Therapy Introduction
7.10.4 Effect Doctors Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.10.5 Effect Doctors Recent Development
7.11 Nadclinic
7.11.1 Nadclinic Company Details
7.11.2 Nadclinic Business Overview
7.11.3 Nadclinic NAD+ Intravenous Therapy Introduction
7.11.4 Nadclinic Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.11.5 Nadclinic Recent Development
7.12 Hydrate IV Bar
7.12.1 Hydrate IV Bar Company Details
7.12.2 Hydrate IV Bar Business Overview
7.12.3 Hydrate IV Bar NAD+ Intravenous Therapy Introduction
7.12.4 Hydrate IV Bar Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.12.5 Hydrate IV Bar Recent Development
7.13 LIVV Natural
7.13.1 LIVV Natural Company Details
7.13.2 LIVV Natural Business Overview
7.13.3 LIVV Natural NAD+ Intravenous Therapy Introduction
7.13.4 LIVV Natural Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.13.5 LIVV Natural Recent Development
7.14 BioReset Medical
7.14.1 BioReset Medical Company Details
7.14.2 BioReset Medical Business Overview
7.14.3 BioReset Medical NAD+ Intravenous Therapy Introduction
7.14.4 BioReset Medical Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.14.5 BioReset Medical Recent Development
7.15 IV Boost UK
7.15.1 IV Boost UK Company Details
7.15.2 IV Boost UK Business Overview
7.15.3 IV Boost UK NAD+ Intravenous Therapy Introduction
7.15.4 IV Boost UK Revenue in NAD+ Intravenous Therapy Business (2021-2026)
7.15.5 IV Boost UK Recent Development
8 NAD+ Intravenous Therapy Market Dynamics
8.1 NAD+ Intravenous Therapy Industry Trends
8.2 NAD+ Intravenous Therapy Market Drivers
8.3 NAD+ Intravenous Therapy Market Challenges
8.4 NAD+ Intravenous Therapy Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global NAD+ Intravenous Therapy Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global NAD+ Intravenous Therapy Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Market NAD+ Intravenous Therapy Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
Table 4. Global NAD+ Intravenous Therapy Revenue (US$ Million) Market Share by Region (2021-2026)
Table 5. Global NAD+ Intravenous Therapy Revenue Share by Region (2021-2026)
Table 6. Global NAD+ Intravenous Therapy Revenue (US$ Million) Forecast by Region (2027-2032)
Table 7. Global NAD+ Intravenous Therapy Revenue Share Forecast by Region (2027-2032)
Table 8. Global NAD+ Intravenous Therapy Market Size by Type (2021-2026) & (US$ Million)
Table 9. Global NAD+ Intravenous Therapy Market Share by Revenue, by Type (2021-2026)
Table 10. Global NAD+ Intravenous Therapy Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 11. Global NAD+ Intravenous Therapy Market Share by Revenue, by Type (2027-2032)
Table 12. Representative Players of Each Type
Table 13. Global NAD+ Intravenous Therapy Market Size by Application (2021-2026) & (US$ Million)
Table 14. Global NAD+ Intravenous Therapy Market Share by Revenue, by Application (2021-2026)
Table 15. Global NAD+ Intravenous Therapy Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 16. Global NAD+ Intravenous Therapy Market Share by Revenue, by Application (2027-2032)
Table 17. New Sources of Growth in NAD+ Intravenous Therapy Applications
Table 18. Global NAD+ Intravenous Therapy Revenue by Players (2021-2026) & (US$ Million)
Table 19. Global NAD+ Intravenous Therapy Market Share by Players (2021-2026)
Table 20. Global Top NAD+ Intravenous Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NAD+ Intravenous Therapy as of 2025)
Table 21. Ranking of Global Top NAD+ Intravenous Therapy Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by NAD+ Intravenous Therapy Revenue (CR5 and HHI) & (2021-2026)
Table 23. Global Key Players of NAD+ Intravenous Therapy, Headquarters and Area Served
Table 24. Global Key Players of NAD+ Intravenous Therapy, Product and Application
Table 25. Global Key Players of NAD+ Intravenous Therapy, Date of Entry into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America NAD+ Intravenous Therapy Revenue by Company (2021-2026) & (US$ Million)
Table 28. North America NAD+ Intravenous Therapy Market Share by Revenue, by Company (2021-2026)
Table 29. North America NAD+ Intravenous Therapy Market Size by Type (2021-2026) & (US$ Million)
Table 30. North America NAD+ Intravenous Therapy Market Size by Application (2021-2026) & (US$ Million)
Table 31. Europe NAD+ Intravenous Therapy Revenue by Company (2021-2026) & (US$ Million)
Table 32. Europe NAD+ Intravenous Therapy Market Share by Revenue, by Company (2021-2026)
Table 33. Europe NAD+ Intravenous Therapy Market Size by Type (2021-2026) & (US$ Million)
Table 34. Europe NAD+ Intravenous Therapy Market Size by Application (2021-2026) & (US$ Million)
Table 35. Asia-Pacific NAD+ Intravenous Therapy Revenue by Company (2021-2026) & (US$ Million)
Table 36. Asia-Pacific NAD+ Intravenous Therapy Market Share by Revenue, by Company (2021-2026)
Table 37. Asia-Pacific NAD+ Intravenous Therapy Market Size by Type (2021-2026) & (US$ Million)
Table 38. Asia-Pacific NAD+ Intravenous Therapy Market Size by Application (2021-2026) & (US$ Million)
Table 39. Latin America NAD+ Intravenous Therapy Revenue by Company (2021-2026) & (US$ Million)
Table 40. Latin America NAD+ Intravenous Therapy Market Share by Revenue, by Company (2021-2026)
Table 41. Latin America NAD+ Intravenous Therapy Market Size by Type (2021-2026) & (US$ Million)
Table 42. Latin America NAD+ Intravenous Therapy Market Size by Application (2021-2026) & (US$ Million)
Table 43. Middle East & Africa NAD+ Intravenous Therapy Revenue by Company (2021-2026) & (US$ Million)
Table 44. Middle East & Africa NAD+ Intravenous Therapy Market Share by Revenue, by Company (2021-2026)
Table 45. Middle East & Africa NAD+ Intravenous Therapy Market Size by Type (2021-2026) & (US$ Million)
Table 46. Middle East & Africa NAD+ Intravenous Therapy Market Size by Application (2021-2026) & (US$ Million)
Table 47. The Wellness Lab Company Details
Table 48. The Wellness Lab Business Overview
Table 49. The Wellness Lab NAD+ Intravenous Therapy Product
Table 50. The Wellness Lab Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 51. The Wellness Lab Recent Development
Table 52. Conciergemdla Company Details
Table 53. Conciergemdla Business Overview
Table 54. Conciergemdla NAD+ Intravenous Therapy Product
Table 55. Conciergemdla Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 56. Conciergemdla Recent Development
Table 57. Azivmedics Company Details
Table 58. Azivmedics Business Overview
Table 59. Azivmedics NAD+ Intravenous Therapy Product
Table 60. Azivmedics Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 61. Azivmedics Recent Development
Table 62. Reset IV Company Details
Table 63. Reset IV Business Overview
Table 64. Reset IV NAD+ Intravenous Therapy Product
Table 65. Reset IV Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 66. Reset IV Recent Development
Table 67. Thedripclub Company Details
Table 68. Thedripclub Business Overview
Table 69. Thedripclub NAD+ Intravenous Therapy Product
Table 70. Thedripclub Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 71. Thedripclub Recent Development
Table 72. Toronto Functional Medicine Centre Company Details
Table 73. Toronto Functional Medicine Centre Business Overview
Table 74. Toronto Functional Medicine Centre NAD+ Intravenous Therapy Product
Table 75. Toronto Functional Medicine Centre Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 76. Toronto Functional Medicine Centre Recent Development
Table 77. Mobileivmedics Company Details
Table 78. Mobileivmedics Business Overview
Table 79. Mobileivmedics NAD+ Intravenous Therapy Product
Table 80. Mobileivmedics Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 81. Mobileivmedics Recent Development
Table 82. Rocky Mountain Ivmedics Company Details
Table 83. Rocky Mountain Ivmedics Business Overview
Table 84. Rocky Mountain Ivmedics NAD+ Intravenous Therapy Product
Table 85. Rocky Mountain Ivmedics Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 86. Rocky Mountain Ivmedics Recent Development
Table 87. Premiumhealth Company Details
Table 88. Premiumhealth Business Overview
Table 89. Premiumhealth NAD+ Intravenous Therapy Product
Table 90. Premiumhealth Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 91. Premiumhealth Recent Development
Table 92. Effect Doctors Company Details
Table 93. Effect Doctors Business Overview
Table 94. Effect Doctors NAD+ Intravenous Therapy Product
Table 95. Effect Doctors Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 96. Effect Doctors Recent Development
Table 97. Nadclinic Company Details
Table 98. Nadclinic Business Overview
Table 99. Nadclinic NAD+ Intravenous Therapy Product
Table 100. Nadclinic Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 101. Nadclinic Recent Development
Table 102. Hydrate IV Bar Company Details
Table 103. Hydrate IV Bar Business Overview
Table 104. Hydrate IV Bar NAD+ Intravenous Therapy Product
Table 105. Hydrate IV Bar Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 106. Hydrate IV Bar Recent Development
Table 107. LIVV Natural Company Details
Table 108. LIVV Natural Business Overview
Table 109. LIVV Natural NAD+ Intravenous Therapy Product
Table 110. LIVV Natural Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 111. LIVV Natural Recent Development
Table 112. BioReset Medical Company Details
Table 113. BioReset Medical Business Overview
Table 114. BioReset Medical NAD+ Intravenous Therapy Product
Table 115. BioReset Medical Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 116. BioReset Medical Recent Development
Table 117. IV Boost UK Company Details
Table 118. IV Boost UK Business Overview
Table 119. IV Boost UK NAD+ Intravenous Therapy Product
Table 120. IV Boost UK Revenue in NAD+ Intravenous Therapy Business (2021-2026) & (US$ Million)
Table 121. IV Boost UK Recent Development
Table 122. NAD+ Intravenous Therapy Market Trends
Table 123. NAD+ Intravenous Therapy Market Drivers
Table 124. NAD+ Intravenous Therapy Market Challenges
Table 125. NAD+ Intravenous Therapy Market Restraints
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. NAD+ Intravenous Therapy Product Picture
Figure 2. Global NAD+ Intravenous Therapy Market Share by Type: 2025 vs 2032
Figure 3. NAD+ Mixed Vitamin Injections Features
Figure 4. Pure NAD+ Injection Features
Figure 5. Global NAD+ Intravenous Therapy Market Share by Application: 2025 vs 2032
Figure 6. Clinic
Figure 7. Hospital
Figure 8. Others
Figure 9. NAD+ Intravenous Therapy Report Years Considered
Figure 10. Global NAD+ Intravenous Therapy Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 11. Global NAD+ Intravenous Therapy Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global NAD+ Intravenous Therapy Market Share by Revenue, by Region: 2021 vs 2025
Figure 13. North America NAD+ Intravenous Therapy Revenue (US$ Million) Growth Rate (2021-2032)
Figure 14. Europe NAD+ Intravenous Therapy Revenue (US$ Million) Growth Rate (2021-2032)
Figure 15. Asia-Pacific NAD+ Intravenous Therapy Revenue (US$ Million) Growth Rate (2021-2032)
Figure 16. Latin America NAD+ Intravenous Therapy Revenue (US$ Million) Growth Rate (2021-2032)
Figure 17. Middle East & Africa NAD+ Intravenous Therapy Revenue (US$ Million) Growth Rate (2021-2032)
Figure 18. Global NAD+ Intravenous Therapy Market Share by Players in 2025
Figure 19. Global Top NAD+ Intravenous Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NAD+ Intravenous Therapy as of 2025)
Figure 20. The Top 10 and 5 Players Market Share by NAD+ Intravenous Therapy Revenue in 2025
Figure 21. North America NAD+ Intravenous Therapy Market Share by Type (2021-2026)
Figure 22. North America NAD+ Intravenous Therapy Market Share by Application (2021-2026)
Figure 23. Europe NAD+ Intravenous Therapy Market Share by Type (2021-2026)
Figure 24. Europe NAD+ Intravenous Therapy Market Share by Application (2021-2026)
Figure 25. Asia-Pacific NAD+ Intravenous Therapy Market Share by Type (2021-2026)
Figure 26. Asia-Pacific NAD+ Intravenous Therapy Market Share by Application (2021-2026)
Figure 27. Latin America NAD+ Intravenous Therapy Market Share by Type (2021-2026)
Figure 28. Latin America NAD+ Intravenous Therapy Market Share by Application (2021-2026)
Figure 29. Middle East & Africa NAD+ Intravenous Therapy Market Share by Type (2021-2026)
Figure 30. Middle East & Africa NAD+ Intravenous Therapy Market Share by Application (2021-2026)
Figure 31. The Wellness Lab Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 32. Conciergemdla Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 33. Azivmedics Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 34. Reset IV Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 35. Thedripclub Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 36. Toronto Functional Medicine Centre Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 37. Mobileivmedics Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 38. Rocky Mountain Ivmedics Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 39. Premiumhealth Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 40. Effect Doctors Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 41. Nadclinic Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 42. Hydrate IV Bar Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 43. LIVV Natural Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 44. BioReset Medical Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 45. IV Boost UK Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021-2026)
Figure 46. Bottom-up and Top-down Approaches for This Report
Figure 47. Data Triangulation
Figure 48. Key Executives Interviewed
Related Reports
Global NAD+ Intravenous Therapy Market Insights, Forecast to 2030
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 449 million by 2030, at a Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period.
Published Date: 2024-11-11
Pages: 154
USD 4900.00
(Single User License)
Global and United States NAD+ Intravenous Therapy Market Report & Forecast 2024-2030
The global NAD+ Intravenous Therapy revenue was US$ 281 million in 2023 and is forecast to a readjusted size of US$ 449 million by 2030 with a CAGR of 7.5% during the review period (2024-2030).
Published Date: 2024-11-11
Pages: 131
USD 4350.00
(Single User License)
Global NAD+ Intravenous Therapy Market Research Report 2024
The global NAD+ Intravenous Therapy market was valued at US$ 281 million in 2023 and is anticipated to reach US$ 449 million by 2030, witnessing a CAGR of 7.5% during the forecast period 2024-2030.
Published Date: 2024-11-11
Pages: 100
USD 2900.00
(Single User License)
Global NAD+ Intravenous Therapy Market Research Report 2025
The global market for NAD+ Intravenous Therapy was valued at US$ 291 million in the year 2024 and is projected to reach a revised size of US$ 479 million by 2031, growing at a CAGR of 7.5% during the forecast period.
Published Date: 2025-03-13
Pages: 97
USD 2900.00
(Single User License)
NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published Date: 2025-03-13
Pages: 125
USD 3950.00
(Single User License)
Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global NAD+ Intravenous Therapy market size was US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published Date: 2025-03-13
Pages: 105
USD 4250.00
(Single User License)
Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 479 million by 2031, at a CAGR of 7.5% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-08-05
Pages: 158
USD 4900.00
(Single User License)
Global NAD+ Intravenous Therapy Market Research Report 2026
The global NAD+ Intravenous Therapy market was valued at US$ 99 million in 2025 and is anticipated to reach US$ 171 million by 2032, at a CAGR of 8.3% from 2026 to 2032.
Published Date: 2026-01-31
Pages: 117
USD 2900.00
(Single User License)
NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 99 million in 2025 and is projected to reach US$ 171 million, growing at a CAGR of 8.3% from 2026 to 2032.
Published Date: 2026-01-31
Pages: 105
USD 3950.00
(Single User License)
Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2032
The global NAD+ Intravenous Therapy market is projected to grow from US$ 99 million in 2025 to US$ 171 million by 2032, at a CAGR of 8.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-26
Pages: 133
USD 4900.00
(Single User License)
Global NAD+ Intravenous Therapy Market Insights, Forecast to 2030
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 449 million by 2030, at a Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period.
Published: 2024-11-11
Pages: 154
USD 4900.00 (Single User License)Global and United States NAD+ Intravenous Therapy Market Report & Forecast 2024-2030
The global NAD+ Intravenous Therapy revenue was US$ 281 million in 2023 and is forecast to a readjusted size of US$ 449 million by 2030 with a CAGR of 7.5% during the review period (2024-2030).
Published: 2024-11-11
Pages: 131
USD 4350.00 (Single User License)Global NAD+ Intravenous Therapy Market Research Report 2024
The global NAD+ Intravenous Therapy market was valued at US$ 281 million in 2023 and is anticipated to reach US$ 449 million by 2030, witnessing a CAGR of 7.5% during the forecast period 2024-2030.
Published: 2024-11-11
Pages: 100
USD 2900.00 (Single User License)Global NAD+ Intravenous Therapy Market Research Report 2025
The global market for NAD+ Intravenous Therapy was valued at US$ 291 million in the year 2024 and is projected to reach a revised size of US$ 479 million by 2031, growing at a CAGR of 7.5% during the forecast period.
Published: 2025-03-13
Pages: 97
USD 2900.00 (Single User License)NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published: 2025-03-13
Pages: 125
USD 3950.00 (Single User License)Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global NAD+ Intravenous Therapy market size was US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published: 2025-03-13
Pages: 105
USD 4250.00 (Single User License)Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 479 million by 2031, at a CAGR of 7.5% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-08-05
Pages: 158
USD 4900.00 (Single User License)Global NAD+ Intravenous Therapy Market Research Report 2026
The global NAD+ Intravenous Therapy market was valued at US$ 99 million in 2025 and is anticipated to reach US$ 171 million by 2032, at a CAGR of 8.3% from 2026 to 2032.
Published: 2026-01-31
Pages: 117
USD 2900.00 (Single User License)NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 99 million in 2025 and is projected to reach US$ 171 million, growing at a CAGR of 8.3% from 2026 to 2032.
Published: 2026-01-31
Pages: 105
USD 3950.00 (Single User License)Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2032
The global NAD+ Intravenous Therapy market is projected to grow from US$ 99 million in 2025 to US$ 171 million by 2032, at a CAGR of 8.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-26
Pages: 133
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4250.00
USD 6375.00
USD 8500.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
Market Segmentation
QYResearch's Strengths
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
Interest In This Report?
Get A Free Sample
Pre-Order Enquiry
OR
Need a Tailored Report?
Customize this report to your needs.
Customize This Report
Fact Checked
Cite this Research